Compare Abbott Laboratories (ABT) vs Novartis AG (NVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Novartis AG — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Novartis AG trades at $155.41 (market cap $298.98B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| ABT | NVS | |
|---|---|---|
Market Cap | $166.94B | $298.98B |
Sector | Health | Health |
52-Week High | $136.62 | $168.62 |
52-Week Low | $82.57 | $113.50 |
Enterprise Value | $193.69B | $339.00B |
Dividend Yield | 2.63% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Novartis (NVS) trades at $157.03, down 1.79% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $56.67B revenue, 23.92% net margin, and robust cash flow generation. Recent developments include multiple strategic acquisitions and regulatory approvals expanding the oncology pipeline, though earnings have shown volatility with two misses in the last four quarters.
NVS presents a balanced investment case with strong profitability and pipeline expansion offset by valuation concerns and earnings inconsistency. The stock offers stability through defensive healthcare exposure but faces execution risks from integration challenges and competitive pressures in pharmaceutical markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
